MicroCyto

Founded in 2021, and based in Beijing, China, MicroCyto Biotechnology (Beijing) Co. , Ltd. , doing business as MicroCyto, operates as a biotechnology company that focuses on R&D, and production of synthetic biology products. The company has production and R&D bases in Qinhuangdao, and the founder Bo Liu graduated from the Institute of Microbiology, Chinese Academy of Science, and has nearly ten years of experience in the field of synthetic biology.

As for 2023, the firm has a team which one-third of the R&D team are PhDs graduated from Chinese Academy of Sciences, Tsinghua University and other institutions, and more than 80% of them have master degrees. In May 2026, it closed a venture funding from Xingyin Investment and individual investors. The company uses low-carbon, energy-efficient and sustainable methods to produce a wide range of compounds for applications in pharmaceuticals, household chemicals, agriculture, food, feed and materials. Specific products include biologically synthesized mannitol, which is anaerobically fermented through synthetic biotechnology, and the fermented product, in addition to mannitol, can be subsequently separated and purified to yield sodium gluconate, gluconolactone or calcium gluconate.

The company utilizes synthetic biotechnology to generate revenues by developing, manufacturing, and marketing compound products with applications in pharmaceuticals, household chemicals, agriculture, food, and other fields. The company plans to use the funding in May 2026 for the acquisition of Yuxin and the large-scale mass production of several bulk products.